Literature DB >> 34553242

Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons.

Naoki Yoshioka1,2, Takahiro Tokuda3, Akio Koyama4, Takehiro Yamada5, Ryusuke Nishikawa6, Kiyotaka Shimamura6, Kensuke Takagi1,2, Yasuhiro Morita1, Akihito Tanaka2, Hideki Ishii2, Itsuro Morishima7, Toyoaki Murohara2.   

Abstract

Both polymer-coated paclitaxel-eluting stents (PC-PESs) and drug-coated balloons (DCBs) are used in conjunction with endovascular therapy (EVT) for the treatment of peripheral artery disease (PAD). We aimed to identify the risk factors for the loss of patency following the use of PC-PES and DCB in a real clinical setting. We assessed the multi-center registry data of 151 lesions from 151 patients who underwent EVT for symptomatic PAD in the superficial femoral and proximal popliteal arteries using PC-PES or DCB. One-year primary patency (PP) and clinically driven target lesion revascularization (CD-TLR) were evaluated using Kaplan-Meier analysis. The predictive risk factors for 1-year outcomes were analyzed using the random survival forest method. PC-PES and DCB were used in 65 (43.0%) and 86 (57.0%) cases, respectively. There were no significant differences in 1-year PP or freedom from CD-TLR between PC-PES and DCB. PP occurred in 85.4% and 80.2% of cases in the PC-PES and DCB groups, respectively (log-rank p = 0.65), while freedom from CD-TLR was noted in 92.7% and 94.1% of cases in the PC-PES and DCB groups, respectively (log-rank p = 0.73). In order of importance, a Clinical Frailty Scale score ≥ 6, female sex, lower proximal vessel diameter, lower body mass index, and younger and older age were identified as predictive risk factors of restenosis in the PC-PES group. Peripheral artery calcification scoring system grade of ≥ 2, post-dissection pattern ≥ D, lower proximal and distal vessel diameter, and lesion length ≥ 100 mm were identified as predictive risk factors of restenosis, in order of importance, in the DCB group. Both PC-PES and DCB were associated with favorable clinical outcomes within 1 year in patients with femoropopliteal artery disease. Furthermore, several factors that could predict restenosis within 1 year following the use of each device were detected.
© 2021. Springer Japan KK, part of Springer Nature.

Entities:  

Keywords:  Drug-coated balloon; Endovascular therapy; Peripheral artery disease; Polymer-coated paclitaxel-eluting stent; Predictor; Restenosis

Mesh:

Substances:

Year:  2021        PMID: 34553242     DOI: 10.1007/s00380-021-01941-9

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  42 in total

1.  Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.

Authors:  Antonio Micari; Marianne Brodmann; Koen Keirse; Patrick Peeters; Gunnar Tepe; Martin Frost; Hong Wang; Thomas Zeller
Journal:  JACC Cardiovasc Interv       Date:  2018-05-28       Impact factor: 11.195

2.  Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.

Authors:  Yvonne Bausback; Tim Wittig; Andrej Schmidt; Thomas Zeller; Marc Bosiers; Patrick Peeters; Steffen Brucks; Aaron E Lottes; Dierk Scheinert; Sabine Steiner
Journal:  J Am Coll Cardiol       Date:  2019-02-19       Impact factor: 24.094

3.  A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.

Authors:  William A Gray; Koen Keirse; Yoshimitsu Soga; Andrew Benko; Anvar Babaev; Yoshiaki Yokoi; Henrik Schroeder; Jeffery T Prem; Andrew Holden; Jeffrey Popma; Michael R Jaff; Juan Diaz-Cartelle; Stefan Müller-Hülsbeck
Journal:  Lancet       Date:  2018-09-24       Impact factor: 79.321

4.  Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.

Authors:  Stefan Müller-Hülsbeck; Koen Keirse; Thomas Zeller; Herman Schroë; Juan Diaz-Cartelle
Journal:  Cardiovasc Intervent Radiol       Date:  2017-09-25       Impact factor: 2.740

5.  Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC).

Authors:  Manesh R Patel; Michael S Conte; Donald E Cutlip; Nabil Dib; Patrick Geraghty; William Gray; William R Hiatt; Mami Ho; Koji Ikeda; Fumiaki Ikeno; Michael R Jaff; W Schuyler Jones; Masayuki Kawahara; Robert A Lookstein; Roxana Mehran; Sanjay Misra; Lars Norgren; Jeffrey W Olin; Thomas J Povsic; Kenneth Rosenfield; John Rundback; Fadi Shamoun; James Tcheng; Thomas T Tsai; Yuka Suzuki; Pascal Vranckx; Bret N Wiechmann; Christopher J White; Hiroyoshi Yokoi; Mitchell W Krucoff
Journal:  J Am Coll Cardiol       Date:  2015-03-10       Impact factor: 24.094

6.  Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease.

Authors:  F Fanelli; A Cannavale; M Gazzetti; P Lucatelli; A Wlderk; C Cirelli; A d'Adamo; F M Salvatori
Journal:  Cardiovasc Intervent Radiol       Date:  2014-05-09       Impact factor: 2.740

7.  International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334.

Authors:  Melissa J Gillett
Journal:  Clin Biochem Rev       Date:  2009-11

8.  Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.

Authors:  Thomas Zeller; Aljoscha Rastan; Roland Macharzina; Gunnar Tepe; Matthias Kaspar; Jorge Chavarria; Ulrich Beschorner; Uwe Schwarzwälder; Thomas Schwarz; Elias Noory
Journal:  J Endovasc Ther       Date:  2014-06       Impact factor: 3.487

9.  COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.

Authors:  Sabine Steiner; Andrej Schmidt; Thomas Zeller; Gunnar Tepe; Marcus Thieme; Lars Maiwald; Henrik Schröder; Wulf Euringer; Matthias Ulrich; Klaus Brechtel; Steffen Brucks; Erwin Blessing; Johannes Schuster; Ralf Langhoff; Sebastian Schellong; Norbert Weiss; Dierk Scheinert
Journal:  Eur Heart J       Date:  2020-07-14       Impact factor: 29.983

10.  Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.

Authors:  John A Laird; Peter A Schneider; Michael R Jaff; Marianne Brodmann; Thomas Zeller; D Chris Metzger; Prakash Krishnan; Dierk Scheinert; Antonio Micari; Hong Wang; Michele Masters; Gunnar Tepe
Journal:  Circ Cardiovasc Interv       Date:  2019-06-14       Impact factor: 6.546

View more
  1 in total

1.  Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study.

Authors:  Zhihong Wang; Lei Sheng; Hongbin Gu; Fan Yang; Huajie Xie; Mingfei Li
Journal:  Front Cardiovasc Med       Date:  2022-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.